Clinical Trials Browser

Active not recruiting × Interventional × Breast Diseases × Clear all

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT07038369 2026-03-17

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Neoplasms, Prostatic Neoplasms, Urogenital Neoplasms, Uterine Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05720039 2026-02-24

SP NSM

Phase NA Active not recruiting

204 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT04784715 2026-02-20

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

Phase 3 Active not recruiting

1,157 enrolled 2 FDA

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis

NCT04711252 2025-10-14

SERENA-4

Phase 3 Active not recruiting

1,370 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Skin Diseases

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

44 enrolled

Breast

Breast Diseases, Breast Neoplasms

NCT04711109 2025-04-02

BRCA-P

Phase 3 Active not recruiting

300 enrolled

Breast

Breast Diseases, Breast Neoplasms, Neoplasms

NCT05441943 2024-03-05

Lymphaticovenous Anastomosis as Treatment for Lymphedema

Phase NA Active not recruiting

10 enrolled

Breast

Breast Cancer Lymphedema, Breast Diseases, Breast Neoplasms, Lymphatic Diseases, Lymphedema, Neoplasms, Pathologic Processes, Postoperative Complications, Skin Diseases

Clinical Trials

SERENA-6

A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations

SP NSM

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

SERENA-4

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

BRCA-P

Lymphaticovenous Anastomosis as Treatment for Lymphedema